The National Medical Commission (NMC) is still reviewing the case against 30 doctors accused of accepting luxury trips abroad, funded by a multinational pharmaceutical company headquartered in the USA. The issue, under the purview of the Ethics and Medical Registration Board (EMRB), remains unresolved as the Board is currently understaffed. The controversy began after the Department of Pharmaceuticals (DoP) received a complaint alleging that the company had financed international trips for selected doctors under the pretext of attending medical conferences. The events — the “Aesthetics & Anti-Aging Medicine World Congress 2024” held in Monaco and Paris — reportedly involved expenses of around Rs.
1.91 crore , covering travel and accommodation. A subsequent investigation by the DoP’s Special Audit Committee confirmed that these expenses were indeed borne by the company. The committee…
